Fig. 1

Low CRNDE suppresses the response to 5-FU/oxaliplatin-based chemotherapy via enhancing autophagy flux in GC patients and the PDX model. a The expression of CRNDE in cisplatin-resistant gastric cancer cell lines and their parental cells were analyzed by GSEA database. b CCK8 assay was used to evaluate the relationship between CRNDE expression and chemosensitivity in 38 cases of GC specimens. c Schematic diagram of PDX model of gastric cancer. d RT-PCR analysis of the expression level of CRNDE in two cases of PDX models. PDX #1 and #2 tumors were subcutaneously injected into the NOD/SCID mice. The mice were treated with oxaliplatin and 5-FU when the tumor volume reached 50 to 100 mm³. The dose of oxaliplatin was 10 mg / kg mice, and 5-FU 50 mg/kg mice were injected intraperitoneally every 3 days for 24 days. The tumor image and tumor inhibition rate (compared to PBS group) of each indicated group are shown (n=5). e Western blot was performed in MGC803 cells treated with different concentrations of oxaliplatin, 5-FU or CQ. f The autophagy and autophagy flow in MGC803 cells was observed by transmission electron microscopy and confocal microscopy when treated with 10 μg/ml oxaliplatin or 400 μg/ml 5-FU. Scale bars, 2 μm (TEM) and 10 μm (confocal microscopy). g Western blot of autophagy marker LC3II expression levels in MGC803 cells transfected with shCRNDE plasmid in the presence of CQ. h Western blot of autophagy marker LC3II expression levels in MGC803 cells transfected with shCRNDE plasmid in the presence of 10 μg/ml oxaliplatin or 400 μg/ml 5-FU. Student’s t-test; mean ± SD; the asterisk (**) indicates P < 0.01